Apologies for fragmented post.
The clinical results from the recent trials do provide evidence of the pre - post clinical findings (impressive and significant improvements achieved with the DURAVR). The clinical results also show superiority over the competitors products...specifically, the mechanical readings - area of valve and pressure gradient.
The cited article (sample of 80 in two groups - mechanical v bioprosthetic valves) highlited a difference between the two......particularly with the exercise tollerence results......the patients recieving the mechanical valve achieved significant improvements in the 6 minute walk test, yet the bioprosthetic valve shows no improvement.
Perhaps this is another area of superiority our product has - the bioprosthetic valve space.
- Forums
- ASX - By Stock
- AVR
- Ann: AGM Chairman Address and CEO Presentation
Ann: AGM Chairman Address and CEO Presentation, page-26
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M |
Open | High | Low | Value | Volume |
$18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $18.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.69 | 53 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 18.500 |
1 | 1000 | 18.400 |
1 | 20 | 18.230 |
1 | 1000 | 18.200 |
1 | 1000 | 18.000 |
Price($) | Vol. | No. |
---|---|---|
18.690 | 53 | 1 |
18.800 | 258 | 1 |
18.900 | 1029 | 2 |
18.910 | 100 | 1 |
19.500 | 21 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online